Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Researchers found that tamoxifen effectively suppresses gynecomastia and breast pain in men with prostate cancer. Treatment with tamoxifen was more successful than with aromatase inhibitors or radiotherapy in reducing breast symptoms.
A study led by Vanderbilt-Ingram Cancer Center finds that black men with prostate cancer receive lower quality surgical care than white men. Black men are less likely to use high-volume surgeons and hospitals, resulting in longer hospital stays and higher mortality rates.
A new study published in The Journal of Urology reports that PSA testing has led to improved survival rates for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body. The disparity between African American and Caucasian men has been resolved, with African American men now having a compara...
A phase III clinical trial shows Enzalutamide extends life by five months, with significant survival benefits and reduced side effects compared to traditional chemotherapy. The study also reveals improved measures including PSA blood levels and progression-free survival.
A recent study published in Carcinogenesis found that cooking red meats at high temperatures, especially pan-frying, increases the risk of advanced prostate cancer. Men who consumed more than two servings of red meat cooked at high temperatures were 40% more likely to develop advanced prostate cancer.
Researchers developed a new prostate cancer screening method that combines drug therapy with changes in PSA levels to identify men with high-risk prostate cancer. The study showed that using PSA with these drugs can help differentiate between prostate cancer and benign disease, even in patients with difficult diagnoses.
Researchers reviewed clinical trials on calcium and vitamin D supplements for men with prostate cancer undergoing hormone therapy, finding that these supplements did not prevent bone loss. The study suggests that these supplements may actually increase the risk of cardiovascular disease and aggressive prostate cancer.
Researchers found two opposing proteins regulating the same set of genes in prostate cancer, suggesting potential therapeutic targets. The study identified genetic markers associated with tumor relapse, which could help predict patient outcomes.
A new study found that over half of malignant prostate cancers have both high-risk HPV 18 and EBV, with HPV alone present in 70% of the cancers. The research suggests a potential collaboration between the two viruses to promote cancer cell survival.
The study suggests that eliminating the PSA test would result in more men being diagnosed with metastatic prostate cancer, leading to higher mortality rates. Prostate cancer death rates have been reduced by nearly 40% over the past 20 years, largely due to early detection through PSA testing.
The study found that without PSA testing, approximately 25,000 cases of advanced prostate cancer would occur in 2008, three times the actual number observed. This would result in more men experiencing aggressive disease with limited treatment options.
A new study from Harvard School of Public Health found that men with prostate cancer are more likely to die from preventable conditions such as heart disease than the disease itself. The study emphasizes the importance of healthy lifestyle changes in prostate cancer management.
Researchers found that paxillin regulates cell growth even in hormone therapy-resistant tumors, providing a new treatment target for advanced prostate cancer. The discovery could potentially lead to the development of targeted therapies that selectively attack cancer cells while leaving healthy cells intact.
Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. The study provides new insight into the mechanism of miR-125b regulation of castrate-resistance prostate cancer.
Researchers have found a new treatment for prostate cancer using gold nanoparticles produced from chemicals in tea leaves, reducing tumors by 80 percent and requiring doses thousands of times smaller than chemotherapy. The nanoparticles are attracted to tumor cells and destroy them efficiently.
A study published in Journal of Biological Chemistry found that prostate cancer cells lacking the protein SPDEF are unable to establish colonies at possible sites of metastasis, highlighting a potential biomarker for untreated cancers. Researchers hope to regulate SPDEF expression to prevent cancer cell metastasis.
Researchers at the University of Houston will pursue projects related to prostate cancer, diabetes, and obesity with funding from the NIH and DOD. The center's eight active NIH grants account for more than $18 million in research funding.
Researchers have discovered a novel mechanism for generating cancer-driving genes, bypassing chromosomal translocation. The SLC45A3-ELK4 fusion RNA promotes prostate cancer cell growth and disease progression in human samples.
A new line of radioisotope therapy, Radium-223 chloride, has been shown to extend the lives of prostate cancer patients with advanced tumors that have spread to bone. The treatment has a short range of penetration and is usually well-tolerated, with serious side effects being rare.
Researchers found African-American survivors have unmet needs in dealing with fears of recurrence, while spouses report concerns about stress and anxiety. The study highlights the importance of culturally appropriate interventions, including improved communication and symptom management for better outcomes.
A team of UC Davis investigators found that a p53 genetic mutation may initiate prostate cancer, differing from the current conventional wisdom. The study developed a mouse model with the mutation, which significantly increased the likelihood of developing prostate cancer.
A new medication, abiraterone acetate, has been shown to slow the spread of metastatic prostate cancer while maintaining quality of life in patients. The study involved 1,088 men and demonstrated improved survival and reduced need for chemotherapy and pain medications.
The CNRCS has awarded three students for their work on prostate cancer, including Jayantha Tennakoon, who aims to identify molecules that provoke cancer cell growth. Undergraduate Hannah Do is maintaining a drug library to isolate new therapeutic targets for advanced prostate cancer. Eylem Aydogdu became the first Ph.D. graduate at the...
A survey of primary care doctors found that many resist stopping routine PSA testing due to patient expectations and malpractice concerns. Researchers are working on a decision-making tool to help doctors make informed choices about prostate cancer screening.
Researchers found that statin users had less prostate growth compared to non-users, regardless of whether they took dutasteride or a placebo. The effect was relatively small and tapered off after two years.
The USPSTF recommends against PSA-based screening for all men regardless of age, citing significant harms associated with the test. The Task Force concludes that the benefits of screening do not outweigh the risks, which include unnecessary treatments and life-long adverse effects.
Researchers have identified a unique molecular subtype of prostate cancer associated with mutations in the SPOP gene, accounting for up to 15% of all cases. The study reveals that these mutations may lead to an accumulation of proteins driving cancer growth.
A study presented at the American Urological Association Annual Meeting found that early stage prostate cancer treatment can alleviate lower urinary tract symptoms (LUTS) in a subgroup of men. Radical prostatectomy surgery was shown to improve urinary function, while radiation therapy and brachytherapy had less favorable effects.
A new UCLA study finds that nerve-sparing surgical techniques and experienced surgeons can improve erectile function after prostate cancer surgery. Surgeons with at least 1,000 cases under their belt and those who actively seek improvement have better outcomes.
A phase II clinical trial found that abiraterone acetate, a hormone-depleting drug, can nearly eliminate or eliminate tumors in patients with aggressive cancers isolated to the prostate gland. The study showed promising results, encouraging further research into new treatments for high-risk prostate cancer.
Researchers will investigate Cu-64, a biomolecule that selectively seeks out a prostate tumor biomarker, to stage prostate cancers and detect recurrent disease accurately. The new technique involves PET scans and could significantly reduce the number of confirmation biopsies.
A new study found that patients undergoing radical prostatectomy surgery in accredited teaching hospitals with residency programs experienced fewer complications than those in non-teaching institutions. Those with private insurance also had better outcomes. The study suggests that specialized care and peer-review processes may contribu...
Research at Henry Ford Hospital found that higher hospital volume and surgeon volume both lead to better surgical results, but hospital volume matters more for older, sicker patients. The study analyzed data from 19,225 Medicare patients with prostate cancer who underwent radical prostatectomy between 1995 and 2005.
A recent study found racial disparities in the results of radical prostatectomy for African American patients compared to white patients. The researchers identified five areas where African Americans had poorer outcomes, including blood transfusions, complications during and after surgery, and prolonged hospital stays.
Researchers identify DNA methylation profiles as potential biomarkers for detecting prostate cancer months earlier than current methods. The discovery also predicts recurrence risk and identifies genes that can be targeted with new drugs.
A new technique has been reported in the American Journal of Pathology that uses genetic abnormalities to predict prostate cancer relapse. The study found that copy number variations (CNVs) in both cancerous and non-cancerous tissues can accurately forecast recurrence, allowing for more targeted treatment approaches.
Research suggests that PSA screening can reduce deaths from prostate cancer in younger, healthy men. The benefit of screening is particularly significant in men with risk factors such as black ancestry or positive family history. Screening may be discontinued for elderly men with multiple comorbidities and limited life expectancy.
Researchers discovered a population of low-PSA prostate cancer stem cells that are resistant to hormone therapy and chemotherapy. These cells can differentiate into other cancer cell types and have long-term tumor-propagating capacity.
A compound isolated from honeybee hive propolis has been found to slow the growth of prostate cancer cells and tumors in mice by shutting down their system for detecting sources of nutrition. The compound CAPE arrests early-stage prostate cancer by suppressing proteins involved in cell proliferation, offering a promising co-treatment a...
A literature review highlights the need for a tailored approach to improving quality of life in subpopulations, including African Americans, Latin Americans, Asians, and men who have sex with men. The authors emphasize the importance of considering demographic, socioeconomic, and sexual preference factors in treatment decision-making.
A new diagnostic tool using gold nanoparticles can determine the aggressiveness of prostate cancer, providing doctors with more accurate information to treat patients. The test has been validated in human tissue samples and could lead to more treatment options if clinical trials begin in two to three years.
The study found that robot-assisted radical prostatectomy (RARP) resulted in superior outcomes compared to open radical prostatectomy (ORP), including reduced need for blood transfusions and complications during or after surgery. RARP patients were also less likely to have prolonged hospital stays.
A study by Long Island University researchers found that carvacrol, an oregano constituent, induces apoptosis in prostate cancer cells. This compound may represent a promising anti-cancer agent with reduced risk of severe side effects due to its common use as food seasoning.
A study confirms that prostate cancer screening is widely ignored in men aged 75 or older, defying 2008 guidelines. Nearly half of men in this age group continue to receive screenings, highlighting the need for selective screening.
A recent study compared the adverse effects of intensity-modulated radiation therapy (IMRT), proton therapy, and conformal radiation therapy in treating localized prostate cancer. The results showed that IMRT was associated with fewer gastrointestinal adverse effects and hip fractures but more erectile dysfunction, while proton therapy...
A study published in JAMA found Intensity Modulated Radiation Therapy (IMRT) to be more effective in reducing certain side effects and preventing cancer recurrence compared to conventional conformal radiation therapy (CRT). IMRT was also comparable to proton therapy, a newer technique.
Researchers study the origins of HIV/AIDS, revealing that SIV replication in human tissues is crucial to viral efficiency. In contrast, a new study finds that autoantibodies against citrullinated proteins contribute to bone loss in rheumatoid arthritis patients.
A study shows a botanical formula significantly suppresses tumor growth in aggressive human prostate cancer cells, demonstrating its safety and effectiveness. The formula inhibits several genes related to cancer proliferation and increases the expression of cancer-fighting genes.
A new study suggests that policies to reduce healthcare costs may compromise quality care by depriving patients of needed services. The research found that regions with high rates of inappropriate imaging also had high rates of appropriate imaging, highlighting the need for a more nuanced approach.
Researchers have identified two inherited-genetic deletions in the human genome that significantly increase a man's risk of developing aggressive prostate cancer. One deletion affects a known gene, while the other is found in non-coding DNA and regulates a cascade of genes.
A new drug developed by Northwestern Medicine scientists has prevented human prostate cancer cells from spreading to other tissues. The drug inhibits movement of the cells and prevents metastasis without causing harm to normal cells or tissues.
A phase II study found metformin reduced fasting glucose, insulin levels and body mass index in men with prostate cancer. The medication also appeared to slow the growth rate of prostate cancer in a proportion of men.
A recent study has found that low oxygen levels in tumors can predict cancer recurrence in men with intermediate-risk prostate cancer. The research, led by radiation oncologists at the Princess Margaret Hospital, suggests that these patients are more likely to develop cancer recurrence within a few years of completing treatment.
Galeterone, a small-molecule oral drug, demonstrated limited side effects and reduced prostate-specific antigen expression in patients with castration-resistant prostate cancer. The drug's triple mechanism of action showed promise in blocking the growth of prostate cancer cells.
A Phase 1 study demonstrated galeterone's tolerability and efficacy in patients with castration-resistant prostate cancer, with minimal toxicities reported. The study showed significant reductions in tumor size and prostate-specific antigen levels in nearly half of the patients evaluated.
Researchers have discovered a new mechanism of prostate cancer cell metabolism by identifying the PFKFB4 gene, which is vital for tumor growth and antioxidant production. The study found that depletion of this gene in laboratory models inhibited tumor growth, suggesting potential targeted therapies.
A recent study conducted at Marshall University investigated the effects of cadmium on the prostate, revealing molecular mechanisms that induce carcinogenesis. The research, published in PLOS ONE, may lead to new therapies for prostate cancer.
Scientists at UC San Diego School of Medicine developed a new strategy for faster anticancer drug discovery by analyzing the genetic pathway of disease. They identified Peruvoside, a cardiac glycoside, as a potential treatment for prostate cancer with minimal side effects.
A new analysis suggests that circumcision before a male's first sexual intercourse may reduce the risk of developing prostate cancer. Men who were circumcised had a 15% lower risk of developing prostate cancer compared to uncircumcised men, with reduced risks for both less aggressive and more aggressive cancers.
Research at Yale University reveals that prostate cancer treatment is often not necessary for older men with short life expectancy. The study found that cancer treatment became more common among men with moderate-risk tumors and shorter life expectancies, despite being unlikely to benefit from it.